Skip to content

Drug interactions

Erdafitinib + Zafirlukast

Severity: Moderate

Erdafitinib and Zafirlukast: moderate interaction.

Last updated

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Zafirlukast inhibits CYP2C9, the main enzyme clearing erdafitinib, so erdafitinib exposure may rise. This may increase toxicities such as hyperphosphatemia, ocular and skin or nail effects, and stomatitis.

What this interaction means in plain words

Erdafitinib and Zafirlukast can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.

Erdafitinib belongs to Oncology; Zafirlukast belongs to Respiratory.

Evidence level: Moderate

Why it happens

Inhibition of CYP2C9-mediated erdafitinib metabolism by zafirlukast.

What to do

Monitor for erdafitinib adverse reactions, including serum phosphate and eye symptoms, and reduce the dose if toxicity occurs. Consider an alternative to zafirlukast such as montelukast.

What to ask your pharmacist

  • Should I take them at different times of day?
  • Does the dose of either medicine need to change?
  • Is there anything I should avoid, such as alcohol or certain foods, while on both?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Erdafitinib and Zafirlukast, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 7 days on the web. No card needed.

Frequently asked questions

Can I take Erdafitinib with Zafirlukast?

MediHelp rates the interaction as moderate. Erdafitinib and Zafirlukast can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Zafirlukast inhibits CYP2C9, the main enzyme clearing erdafitinib, so erdafitinib exposure may rise. This may increase toxicities such as hyperphosphatemia, ocular and skin or nail effects, and stomatitis.

How serious is the interaction between Erdafitinib and Zafirlukast?

MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor for erdafitinib adverse reactions, including serum phosphate and eye symptoms, and reduce the dose if toxicity occurs. Consider an alternative to zafirlukast such as montelukast.

What other medicines interact with Zafirlukast?

MediHelp also lists interactions of Zafirlukast with, for example, Pimozide, Lomitapide, Nilotinib. The full list is on the Zafirlukast page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in